List of Immuno-Oncology Companies in Pennsylvania - 14

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia. Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzyme’s modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Avammune Therapeutics is a drug discovery company focused on the development of novel immunotherapeutics to address high unmet medical needs. Our research is driven by the science that have a potential to create a significant difference on the disease platform. Our expertise lies on developing small molecule drugs that can be administered systemically and can potentially overcome the issues faced by the currently available therapeutics for cancer and immunological disorders. We work with experts in disease biology to achieve this goal which aims at improving the lives of patients significantly. Our research efforts has led to successful completion of projects in the immunoncology space.

Specialty oncology-focused biopharmaceutical company based in Malvern, PA with a broad pipeline encompassing novel best in class selective HDAC6i immunomodulators and a game changing myeloid based discovery platform. Avstera focuses on foundational tumor biology science, while methodologically breaking barriers using cutting-edge approaches in order to deliver impactful treatments to cancer patients.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus' natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir's cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh's world-class oncolytic virus and immunotherapy research programs.

LabyRx Immuno-Oncology is a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas, a class of glandular-related tumors that represent approximately 40% of worldwide cancer cases and 50% of treatment-related spending. Based upon our scientists' discovery and ongoing research into the unique adenocarcinoma target – Labyrinthin – the Company aims to advance novel cancer therapeutic technologies that improve treatment processes. The team comprise renown scientists in the United States and Hong Kong working towards cancer therapeutics and diagnostics.

Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.

Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer

Ocean Genomics works with biopharma, academic researchers and advocacy to empower discovery and development. We provide our advanced computing platforms for gene expression analysis, and biomarker and target discovery, and our vast and fast-growing gene expression database. We also provide integrated programs ranging from single experiment analyses to multi-milestone efforts that include computational biologists, and use of all of our platforms, AI models and data assets.

Reaction Biology provides scientists worldwide with a trusted research partner supporting all phases of preclinical drug discovery from target validation through hit identification, hit to lead and lead optimization. Our portfolio covers most of your needs in drug discovery – over 2,000 biochemical targets, hundreds of cell-based assays, an extensive array of in vivo oncology models, along with custom assay development and protein production. Our team of Ph.D. scientists will provide you with collaborative support, quality data, and excellent communication, for a superior research result. Our target categories include kinases, epigenetic targets, proteases, PARPs, and many more. We also offer a line of high-quality epigenetic and kinase proteins for sale. Assay platforms include radiolabeled and fluorescent biochemical assays, biophysical assays, ion channel, cell-based assays including a wide array of target engagement assays, and in vivo oncology models including our SubQperior tumor models. From our labs in the US and Germany, Reaction Biology performs research projects for customers around the globe on a fee-for-service basis and as an integrated partner, and we would be delighted to support your research needs, too. Let's discover together.

Treovir was established in 2019 to develop and commercialize G207, an oncolytic HSV virus for the treatment of pediatric brain tumors. A Phase 1 clinical trial has been completed demonstrating strong evidence of safety and efficacy. Treovir will launch a Phase 2 clinical study for G207 in 2023 that is designed to seek market approval to treat pediatric patients with recurrent pediatric gliomblastoma. Pediatric Brain Tumors are the most common form of solid tumor in children. More than 3,400 children are diagnosed every year. Outcomes for children with high-grade glioma are poor despite surgery, radiation and chemotherapy, which produce devastating neurotoxicities in a child’s developing brain. There has been a complete lack of therapeutic advances in the past 15 years, and the median survival at tumor recurrence is less than 6 months. The G207 therapy consists of a single infusion directly into the tumor. The immunotherapy approach causes direct tumor cell death and also recruits immune system cells to aid the body’s own natural tumor defenses. In a Phase 1 clinical trial in 12 patients, G207 therapy saw Improved overall survival of 12.2 months versus 5.6 months for historical trials. There was also a dramatic safety advantage with no serious adverse events observed. Significantly, evidence of florid T-cell response in treated tumors turning immunologically “cold” tumors “hot” was also observed indicating the body's own immune system was activated against the tumors.